Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today ...
Health care professionals can have a powerful impact on labeling requirements for drugs by formally petitioning the FDA for ...
Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire ...
This article was reviewed by Sara Harcharik Perkins, MD. Spironolactone for Hair Loss: Benefits, Dosage, and Risks Key ...
BeOne Medicines AG is rated Strong Buy as Brukinsa and Tevimbra drive robust growth and pipeline catalysts approach. Learn ...
The Food and Drug Administration (FDA) has approved updated labeling for Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic ...
The EMA (European Medicines Agency), FDA and WHO identified semaglutide suicidal thought reports, exceeding those of other ...
When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen | ...
Zymeworks advances with strong Phase III Ziihera data, royalty-driven growth, solid cash, updated buy and sell levels. See why ZYME stock is a buy.
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback